New mechanism for increased levels of metastatic chemokine receptors revealed
Thomas Slagsvold, a postdoctoral fellow in Harald Stenmarks group, has recently published in EMBO Journal (impact factor 10,053) a paper that sheds light on how the cellular levels of the chemokine receptor CXCR4 are increased in cancers. This issue is of considerable interest because enhanced expression of CXCR4 has been strongly associated with metastasis of breast cancer cells to lung tissue.
Recent studies by others had shown that HER2, a member of the epidermal growth factor receptor family that strongly increases the aggressiveness of breast tumours, causes increased cellular CXCR4 levels by stimulating PI 3-kinase, an enzyme that phosphorylates a specific phospholipid to yield the lipid product known as PIP3. A collaborative project between Stenmarks group and Adriano Marchese, a CXCR4 expert at the Loyola University of Chicago, had previously revealed that the ubiquitin ligase AIP4 is crucial for the degradation of CXCR4 by ubiquitinating the receptor and thus targeting it for degradation in lysosomes (Marchese et al., Dev.Cell 2003). In the present EMBO Journal paper, Slagsvold and co-workers collaborated with Marchese to show that a protein kinase activated by PIP3, PDK1, activates another protein kinase, CISK. CISK in turn regulates AIP4 through phosphorylation of specific residues and thus prevents targeting of CXCR4 to the degradative lysosomes. This is likely to be part of the reason why CXCR4 levels are increased in HER2-overexpressing tumours and might provide a novel therapeutic target.
From major journals, first or last author from the Institute for Cancer Research
Bergholtz H, Carter JM, Cesano A, Cheang MCU, Church SE, Divakar P, Fuhrman CA, Goel S, Gong J, Guerriero JL, Hoang ML, Hwang ES, Kuasne H, Lee J, Liang Y, Mittendorf EA, Perez J, Prat A, Pusztai L, Reeves JW, Riazalhosseini Y, Richer JK, Sahin Ö, Sato H, Schlam Iet al.(2021) Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMx® Digital Spatial Profiler Cancers (Basel), 13(17) DOI 10.3390/cancers13174456, PubMed 34503266
Taavitsainen S, Engedal N, Cao S, Handle F, Erickson A, Prekovic S, Wetterskog D, Tolonen T, Vuorinen EM, Kiviaho A, Nätkin R, Häkkinen T, Devlies W, Henttinen S, Kaarijärvi R, Lahnalampi M, Kaljunen H, Nowakowska K, Syvälä H, Bläuer M, Cremaschi P, Claessens F, Visakorpi T, Tammela TLJ, Murtola Tet al.(2021) Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse Nat Commun, 12(1), 5307 DOI 10.1038/s41467-021-25624-1, PubMed 34489465
Møller P, Sampson JR, Dominguez-Valentin M, Seppälä TT(2021) Towards evidence-based personalised precision medicine for Lynch syndrome Lancet Oncol, 22(9), e383 DOI 10.1016/S1470-2045(21)00400-9, PubMed 34478667
Fromm B, Tarbier M, Smith O, Mármol-Sánchez E, Dalén L, Gilbert MTP, Friedländer MR(2021) Corrigendum: Ancient microRNA profiles of 14,300-yr-old canid samples confirm taxonomic origin and provide glimpses into tissue-specific gene regulation from the Pleistocene RNA, 27(10), 1291 DOI 10.1261/rna.078885.121, PubMed 34531318
Krzyscik MA, Zakrzewska M, Sørensen V, Øy GF, Brunheim S, Haugsten EM, Mælandsmo GM, Wiedlocha A, Otlewski J(2021) Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model Biomacromolecules(in press) DOI 10.1021/acs.biomac.1c00662, PubMed 34542998
Yaqub S, Bjørnbeth BA, Angelsen JH, Fristrup CW, Grønbech JE, Hemmingsson O, Isaksson B, Juel IS, Larsen PN, Lindell G, Mortensen FV, Mortensen KE, Rizell M, Sandström P, Sandvik OM, Sparrelid E, Taflin H, Taskén K, ASAC study group(2021) Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial Trials, 22(1), 642 DOI 10.1186/s13063-021-05587-w, PubMed 34544470